| Name | Menin-MLL inhibitor MI-2 |
| Description | Menin-MLL inhibitor MI-2 (MI2) is a potent menin-MLL interaction inhibitor with IC50 of 446 nM. |
| Cell Research | The MLL-AF9 and E2A-HLF transduced murine BMC are plated in 12-well plates at the concentration of 5×103 cells/mL with 1 mL methylcellulose medium M3234 containing 20% IMDM medium, 1% penicillin/streptomycin, IL-3 and 0.25% DMSO or compounds. 6 days later colonies are stained with 100 μL iodonitrotetrazolium chloride at final concentration of 1 mg/mL, incubated at 37°C for 30 min and counted. To replate for the 2nd round, colonies are counted at day 6 without staining and cells were washed out by 1×PBS buffer and resuspended in IMDM medium containing 15% FBS, 1% penicillin/streptomycin and IL-3. 5×103 cells are plated in 12-well plates with 1ml methycellulose medium M3234 containing 20% IMDM medium, 1% penicillin/streptomycin, IL-3 and 0.25% DMSO or compounds. 6 days later colonies are stained and counted.(Only for Reference) |
| Kinase Assay | High Throughput Screening: FITC-MBM1 at 15 nM and menin at 150 nM in the FP buffer are mixed and incubated for 1h in the dark at room temperature. For point screening, the 0.2 μL of each compound (20 μM final concentration, 1% DMSO) is added to 20 μL of the aliquot of the protein-peptide mixture and incubated on 384-well plates in the dark at room temperature for 1h. In confirmation screening, the serial dilution plates with compounds in DMSO are prepared and used to titrate the menin-FITC-MBM1 complex. Change in fluorescence polarization is monitored at 525 nm after excitations at 495 nm using the PHERAstar microplate reader (BMG) and applied to determine IC50 values with the Origin 7.0 program. |
| In vivo | MI-2 effectively inhibits cell proliferation and induces apoptosis in human MLL leukemia cell lines bearing various MLL translocations. In HEK293 cells, MI-2 penetrates its protein target, efficiently inhibiting the interaction between menin and MLL-AF9. By downregulating the expression of target genes essential for the oncogenic activity of MLL fusion proteins, MI-2 effectively blocks leukemia transformation mediated by MLL fusion proteins. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 70 mg/mL (186.4 mM)
H2O : < 1 mg/mL (insoluble or slightly soluble)
Ethanol : 70 mg/mL (186.4 mM)
|
| Keywords | Menin MLL inhibitor MI 2 | Apoptosis | Inhibitor | Epigenetic Reader Domain | inhibit | Menin-MLL inhibitor MI-2 | MeninMLL inhibitor MI2 |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Acetylcysteine | Kaempferol | Myricetin | Sodium 4-phenylbutyrate | L-Ascorbic acid | Dextran sulfate sodium salt (MW 4500-5500) | Metronidazole | Sorafenib | Tributyrin | Curcumin |
| Related Compound Libraries | Apoptosis Compound Library | Histone Modification Compound Library | Reprogramming Compound Library | Methylation Compound Library | Bioactive Compound Library | Chromatin Modification Compound Library | Inhibitor Library | Stem Cell Differentiation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max |
United States
